Porphyrin Or Derivative Thereof Patents (Class 424/9.61)
-
Patent number: 11452740Abstract: Systems and methods for developing and applying photosynthetic cellular substances to a human or animal for medical, therapeutic or cosmetic uses are provided. Photosynthetic cells, such as algal cells, can be used in these substances to provide the ability to continuously generate oxygen when exposed to a light source or other oxygen-generating trigger. The substances can be developed as a standalone liquid, gel or cream, or embedded within a bandage, mesh, scaffold or other structure with a light source to promote oxygen production. The substances can be applied topically for medical, therapeutic or cosmetic treatments, or injected internally for generation of oxygen within one or more parts of the body.Type: GrantFiled: September 3, 2015Date of Patent: September 27, 2022Inventor: Jose-Tomas Egana-Erazo
-
Patent number: 10952621Abstract: Embodiments herein relate to optoelectronic interfaces for multimode analyte sensors for use with implantable medical devices. In an embodiment, an implantable medical device is included. The implantable medical device can include a first chemical sensor including an optical excitation assembly comprising a first visible spectrum emitter, a second visible spectrum emitter, and at least one of a near-infrared (NIR) emitter and an ultraviolet emitter. The first chemical sensor can also include an optical detection assembly including a colorimetric response detector, and a photoluminescent response detector. The first chemical sensor can also include a multimode sensing element including a colorimetric response element specific for a first chemical analyte, a photoluminescent response element specific for a second chemical analyte. Other embodiments are also included herein.Type: GrantFiled: September 20, 2018Date of Patent: March 23, 2021Assignee: Cardiac Pacemakers, Inc.Inventors: Michael J. Kane, Keith R. Maile, Yingbo Li, Jean M. Bobgan
-
Patent number: 10772546Abstract: Some embodiments described herein relate to a sensor that includes a first a first polymer-luminescent sensing compound configured to produce a first luminescent signal in the presence of a first analyte and a second polymer-luminescent sensing compound configured to produce a second luminescent signal in the presence of a second analyte. The second luminescent signal can have a luminescent lifetime that is at least 1.1 times greater than a luminescent lifetime of the first luminescent signal. Such temporally differences in signal can be used to deconvolute the first luminescent signal from the second luminescent signal even when, for example, the first luminescent signal and the second luminescent signal have the same or a similar emission spectrum.Type: GrantFiled: June 29, 2018Date of Patent: September 15, 2020Assignee: Profusa, Inc.Inventors: Mary K. Balaconis, Scott Nichols, Sierra Guidry, Yu Zhang, Ryan Schweller, Soya Gamsey, Jacob William Clary, Sulolit Pradhan, Natalie Wisniewski
-
Patent number: 10570173Abstract: Compounds useful as contrast agents in image-guided surgery are provided. The compounds comprise a latent cationic lysosomotropic fragment that is detectable upon cleavage by lysosomal proteases within treated tissues, particularly within tumors and other diseased tissues. Also provided are compositions comprising the compounds and methods for using the compounds, for example in dynamically monitoring protease activity in vivo during image-guided tumor resection surgery.Type: GrantFiled: January 22, 2016Date of Patent: February 25, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Matthew S. Bogyo, Martijn Verdoes, Leslie Ofori, Nimali P. Withana
-
Patent number: 10522764Abstract: The present invention relates to a compound, and a light-emitting element and an electronic device including the same, and, more particularly, to a compound for an organic light-emitting element, and a light-emitting element and an electronic device including the same. The compound according to the present invention can improve hole injection and/or transport abilities.Type: GrantFiled: August 9, 2013Date of Patent: December 31, 2019Assignee: LMS Co., Ltd.Inventors: Jeong Og Choi, Oh Kwan Kwon, Joon Ho Jung
-
Patent number: 9670217Abstract: The disclosed subject matter includes methods of preparation, properties, pharmaceutical compositions and methods of therapy of sulfonated chlorins and bacteriochlorins designed for the photodynamic therapy (PDT) of hyperproliferative tissues such as tumors, hyperproliferative blood vessels and other disorders or abnormalies that are responsive to PDT. In particular, the economical large-scale synthesis of stable chlorins and bacteriochlorins is described. Their properties were tailored to meet those of ideal photosensitizers for PDT. In another embodiment, pharmaceutical compositions and methods of therapy for systemic administration are provided. In a further embodiment, pharmaceutical compositions and methods of therapy for topical administration are also provided. Further provided is a method of labeling a target tissue and providing an image of that tissue by fluorescence of magnetic resonance imaging.Type: GrantFiled: October 22, 2009Date of Patent: June 6, 2017Assignee: UNIVERSIDADE DE COIMBRAInventors: Luis Guilherme Da Silva Arnaut Moreira, Maria Miguéns Pereira, Sebastião José Formosinho SanchesSimõs, Sérgio Paulo Magalhães Simões, Grazyna Stochel, Krystyna Urbanska
-
Patent number: 9238006Abstract: Provided is a pharmaceutical composition containing inorganic nanoparticles selected from titanium oxide nanoparticles or silica nanoparticles as an active ingredient for preventing or treating angiogenesis-related diseases. The pharmaceutical composition for preventing or treating angiogenesis-related diseases according to the present invention may be used as a therapeutic agent for various diseases based on angiogenesis such as age-related macular degeneration, tumors, and diabetes-related complications.Type: GrantFiled: September 20, 2012Date of Patent: January 19, 2016Assignee: KOREA RESEARCH INSTITUTE OF STANDARDS AND SCIENCEInventors: Tae Geol Lee, Jeong Hun Kim, Dong Hyun Jo
-
Publication number: 20150132230Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.Type: ApplicationFiled: January 26, 2015Publication date: May 14, 2015Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel
-
Publication number: 20150071862Abstract: Functionalized fluorine containing phthalocyanine molecules, methods of making, and methods of use in diagnostic applications and disease treatment are disclosed herein. In some embodiments, the fluorine containing phthalocyanine molecules are functionalized with a reactive functional group or at least one cancer-targeting ligand (CTL). The CTL can facilitate more efficient binding and/or internalization to a cancer cell than to a healthy cell. The CTL can inhibit expression of oncoprotein in some embodiments. The pthalocyanine moiety can be used in diagnostic applications, such as fluorescence labeling of a cancer cell, and/or treatment applications, such as catalyzing formation of a reactive oxygen species (ROS) which can contribute to cell death of a cancer cell.Type: ApplicationFiled: September 9, 2014Publication date: March 12, 2015Inventors: David Sabatino, Sergiu M. Gorun, Emily Borland, Hemantbhai Patel, Pradeepkumar Patel
-
Patent number: 8859760Abstract: Described herein are methods and compositions for killing or preventing the growth of microbes. It has been discovered that a class of porphyrins can kill or prevent the growth of microbes. The porphyrins can be used in a number of different applications where microbes grow.Type: GrantFiled: December 12, 2013Date of Patent: October 14, 2014Assignee: Frontier Scientific, Inc.Inventors: Glenn Prestwich, Jerry C. Bommer, Charles Testa
-
Publication number: 20140294735Abstract: The present invention provides a fluorescent molecular probe for efficient fluorescent detection (visualization) of tumors or for implementing fluorescent detection and photodynamic treatment, more specifically, the present invention provides a macromolecular fluorescent molecular probe for fluorescent detection of tumor, comprising a complex comprising a fluorescent molecule and a biocompatibie macromolecule.Type: ApplicationFiled: September 5, 2012Publication date: October 2, 2014Inventors: Hiroshi Maeda, Makoto Hashizume, Jun Fang, Hideaki Nakamura, Haibo Qin, Steffen Hackbarth, Masaharu Murata
-
Publication number: 20140286875Abstract: Oxygen sensing luminescent dyes, polymers and sensors comprising these sensors and methods of using these sensors and systems are provided.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicant: Profusa, Inc.Inventors: Soya Gamsey, Natalie Wisniewski, Kristen Helton, William McMillan
-
Publication number: 20140255317Abstract: Provided is a compound represented by the general formula (1) (where: G represents a hexose-6-phosphate residue; and L represents a divalent linker group).Type: ApplicationFiled: September 5, 2012Publication date: September 11, 2014Applicant: KYOTO UNIVERSITYInventors: Keita Un, Mitsuru Hashida, Shigeru Kawakami, Makoto Kiso, Akiharu Ueki, Hiromune Ando
-
Publication number: 20140154186Abstract: Compound of Formula I: are described, along with compositions containing the same and methods of use thereof.Type: ApplicationFiled: May 30, 2012Publication date: June 5, 2014Applicant: North Caroliina State UniversityInventors: Jonathan S. Lindsey, Michael Krayer
-
Publication number: 20140147380Abstract: Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed.Type: ApplicationFiled: October 18, 2013Publication date: May 29, 2014Applicant: Thomas Jefferson UniversityInventors: Hank Wolfe, Scott A. Waldman
-
Patent number: 8679459Abstract: Tetrapyrrolic photosensitizers and imaging agent compounds having A, B, C, and D rings and having a reduced B ring and an oxidized D ring. The compounds preferably have a purity of at least 95 percent and preferably have a fused system connected at an unsaturated carbon atom of the C ring nearest the D ring and at the unsaturated carbon atom between the C and D rings. The invention also includes a method of making the compounds at over 95 percent yield by starting with a B and D ring oxidized tetrapyrollic compound and dissolving it in a halogenated hydrocarbon solvent and treating it with sufficient nitroalkane solution of FeCl36H2O to oxidize the D ring and separating the resulting organic layer and drying.Type: GrantFiled: February 19, 2009Date of Patent: March 25, 2014Assignee: Health Research, Inc.Inventors: Ravindra K. Pandey, Chao Liu, Mahabeer Dobhal, William Potter, Janet Morgan, Stephanie Pincus
-
Patent number: 8633311Abstract: Described herein are methods and compositions for killing or preventing the growth of microbes. It has been discovered that a class of porphyrins can kill or prevent the growth of microbes. The porphyrins can be used in a number of different applications where microbes grow.Type: GrantFiled: July 29, 2009Date of Patent: January 21, 2014Assignee: Frontier Scientific, Inc.Inventors: Jerry C. Bommer, Glenn Prestwich, Charles Testa
-
Patent number: 8620409Abstract: A system and method for confocal imaging of tissue in vivo and in situ, e.g., for minimally invasive diagnosis of patients. A catheter is provided that has a dye carrier coupled to the distal end of a fiber optics bundle, which allows for the introduction of at least one fluorescent dye therein the dye carrier into a portion of the tissue of interest of a subject or patient when the dye carrier is selectively brought into contact with the portion of the tissue of interest. The resulting confocal images permit the acquisition of diagnostic information on the progression of diseases at cellular/tissue level in patients. Furthermore, a system for ECG-triggered image acquisition is provided.Type: GrantFiled: August 4, 2009Date of Patent: December 31, 2013Assignee: University of Utah Research FoundationInventors: Frank B. Sachse, John H. Bridge, Robert Hitchcock
-
Patent number: 8568694Abstract: A new class of micro- and nano-particulate paramagnetic spin probes especially useful for magnetic resonance imaging techniques, including electron paramagnetic resonance (EPR) and magnetic resonance imaging (MRI). The probes are lithium phthalocyanine derivative compounds. Also provided are suspensions and emulsions comprising lithium phthalocyanine derivative probes. Also provided are noninvasive methods for measuring noninvasive methods of measuring oxygen concentration, oxygen partial pressure, oxygen metabolism, and nitric oxide concentration in a specific tissue, organ, or cell in vivo or in vitro.Type: GrantFiled: January 15, 2010Date of Patent: October 29, 2013Assignee: The Ohio State University Research FoundationInventors: Periannan Kuppusamy, Ramasamy P. Pandian, Narasimham L. Parinandi, Jay L. Zweier
-
Patent number: 8562944Abstract: A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and an imaging agent and methods for making and using same.Type: GrantFiled: October 21, 2010Date of Patent: October 22, 2013Assignees: Health Research, Inc., The Research Foundation of State University of NY, Regents of the University of MichiganInventors: Ravindra K. Pandey, Raoul Kopelman, Anurag Gupta, Munawwar Sajjad
-
Patent number: 8540967Abstract: Porphyrazines capable of localizing in a tumor of a mammal are disclosed. The porphyrazines are used in methods of imaging a tumor and in methods of treating tumors, either alone or in combination with a chemotherapeutic agent and/or radiation.Type: GrantFiled: September 4, 2009Date of Patent: September 24, 2013Assignee: Hoffman/Barrett, L.L.C.Inventors: Anthony G. M. Barrett, Evan R. Trivedi, Brian M. Hoffman
-
Patent number: 8524239Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: GrantFiled: July 11, 2011Date of Patent: September 3, 2013Assignee: The United States of America as represented by the Secrectary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Makoto Mitsunaga, Marcelino Bernardo
-
Publication number: 20130202525Abstract: A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and a postloaded imaging agent and methods for making and using same.Type: ApplicationFiled: August 3, 2012Publication date: August 8, 2013Applicants: Health Research, Inc., Regents of the University of Michigan, The Research Foundation of State University of New YorkInventors: Ravindra K. Pandey, Raoul Kopelman, Anurag Gupta, Munawwar Sajjad
-
Publication number: 20130195758Abstract: A PAA nanoparticle containing a covalently linked fluorescent dye and a post-loaded tetrapyrrolic photosensitizer.Type: ApplicationFiled: August 3, 2012Publication date: August 1, 2013Applicants: HEALTH RESEARCH, INC., Regents of the University of Michigan, The Research Foundation of State University of New YorkInventors: Ravindra K. Pandey, Raoul Kopelman, Anurag Gupta, Munawwar Sajjad
-
Patent number: 8461142Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<?>, COS<?>, SO3<?>, PO3<2?>, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.Type: GrantFiled: November 9, 2010Date of Patent: June 11, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: Avigdor Scherz, Alexander Brandis, Ohad Mazor, Yoram Salomon, Hugo Scheer
-
Publication number: 20120308485Abstract: The present invention provides novel porphyrin derivatives represented by the general formula 1 and/or pharmaceutically acceptable derivatives thereof as NIR sensitizers for photodynamic therapeutic and diagnostic, biological and industrial applications. These porphyrin derivatives posses absorption (400-700 nm) and emission (600-750 nm) in the regions where biological chromophores do not absorb and hence are ideal candidates for application as NIR PDT agents and fluorescence sensors for medicinal applications in biology. The substituents like hydroxyl and glycolic units on these dyes render them amphiphilicity thereby improving their solubility in the aqueous media and cellular uptake and localization. These dyes show no toxicity in the dark and are highly selective towards tumor cells and stain nucleus very rapidly. Accordingly, these porphyrin derivatives are extremely useful as NIR PDT fluorescence sensors in photodynamic therapeutic and diagnostic, biological and industrial applications.Type: ApplicationFiled: January 21, 2011Publication date: December 6, 2012Applicant: Council of Scientific and Industrial ResearchInventors: Danaboyina Ramaiah, Suneesh C. Karunakaran, Jisha S. Vadakkancheril, Chandrashekar K. Tavarekere, Srinivasan Alagar, Madhavan Radhakrishna Pillai, Sivakumari Asha Nair, Saneesh Babu P. Saras, Mohan Chintalagiri Rao, Kunchala Sridhar Rao
-
Patent number: 8273874Abstract: The invention relates to an improved method of dynamic nuclear polarisation (DNP) of carboxylic acids and to compounds and compositions for use in the method.Type: GrantFiled: August 29, 2007Date of Patent: September 25, 2012Assignee: GE Healthcare ASInventors: Christian Gloegaard, Rolf Servin, Mikkel Thaning
-
Publication number: 20120232463Abstract: A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.Type: ApplicationFiled: April 10, 2012Publication date: September 13, 2012Inventors: Han-Je Kim, Jonathan S. Lindsey
-
Patent number: 8207212Abstract: Methods for preventing damage to the epidermis during PDT induced using a pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control formation of a photoactive species from a topically-applied pre-photosensitizing agent. In one embodiment, thermal inhibition is used to prevent the metabolism of a pre-photosensitizing agent in epithelial tissue surrounding a treatment site. In another embodiment, a chemical inhibitor can be applied to the epithelial tissue to inhibit the conversion of a pre-photosensitizing agent into a phototoxic species.Type: GrantFiled: December 21, 2009Date of Patent: June 26, 2012Assignee: The General Hospital CorporationInventors: Richard Rox Anderson, Bernhard Ortel, Eliot F. Battle, Edwin K. Joe
-
Patent number: 8158669Abstract: The present invention describes an improved photodynamic treatment to treat subfoveal choroidal neovascularization (CNV).Type: GrantFiled: October 18, 2007Date of Patent: April 17, 2012Assignee: QLT, Inc.Inventor: Romulus K Brazzell
-
Publication number: 20120064012Abstract: Fluorescent microspheres for the measurement of blood flow are provided. The microspheres are substantially uniform in diameter and have a hydrophobic surface, which allows them to circulate more freely throughout bloodstream, while reducing immunogenicity, particle aggregation and bioaccumulation. The hydrophobic surface on each microsphere is generally comprised of polymeric material having a limited surface charge.Type: ApplicationFiled: August 15, 2011Publication date: March 15, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventor: Yu-Zhong Zhang
-
Patent number: 8133482Abstract: The present invention relates to the field of conjugates comprising a substrate which is attached to at least one photoactivatable killing agent and at least one first quencher, and methods for their use. More particularly, the present invention relates to photodynamic therapy agents. The invention further relates to methods for decontaminating blood and methods for treating cancer or viral infection in a subject using the conjugates of the present invention.Type: GrantFiled: May 15, 2006Date of Patent: March 13, 2012Assignee: The Trustees of the University of PennsylvaniaInventors: Gang Zheng, Jerry P. Glickson, Britton Chance, Edward James Delikatny, Klara Stefflova, Juan Chen
-
Publication number: 20120020893Abstract: The invention is directed to a probe-type imaging device useful to visualize interior surfaces, e.g., the lumen of blood vessels. Specifically, the probe-type device is particularly useful for direct tissue imaging in the presence or absence of molecular imaging agents.Type: ApplicationFiled: October 4, 2011Publication date: January 26, 2012Inventors: David R. Elmaleh, Rick A. Rogers, Hjalmar Brismar
-
Patent number: 8097609Abstract: Porphyrinic compounds that contain solubilizing groups are described, along with methods of making and using the same and compositions comprising such compounds. Examples of such compounds include compounds of Formula (I) wherein: Z is a porphyrinic macrocyclic, Alk1 and Alk2 are each independently an alkylidene chain; L is a linking group or is absent; R1 is preferably an ionic group or polar group; R2 is an ionic group, polar group, bioconjugatable group, or targeting group: R3 is present or absent and when present is a halo group, bioconjugatable group, or targeting group, n is O or 1 (that is, the CH group is present, or Alk1 and Alk2 are bonded directly to a carbon of the porphyrinic macrocycle Z); or a salt thereof.Type: GrantFiled: October 19, 2006Date of Patent: January 17, 2012Assignee: North Carolina State UniversityInventors: K. Eszter Borbas, Jonathan S. Lindsey
-
Publication number: 20110319808Abstract: A composition for use on skin and wounds, comprising a photo-catalyst which is capable of preferentially staining biofilms the composition being for use in the diagnosis and treatment of biofilms in wounds.Type: ApplicationFiled: December 18, 2009Publication date: December 29, 2011Applicant: ConvaTec Technologies Inc.Inventors: Phillip Godfrey Bowler, Daniel Gary Metcalf, David Parsons
-
Publication number: 20110293531Abstract: Porphyrazines capable of localizing in a tumor of a mammal are disclosed. The porphyrazines are used in methods of imaging a tumor and in methods of treating tumors, either alone or in combination with a chemotherapeutic agent and/or radiation.Type: ApplicationFiled: September 4, 2009Publication date: December 1, 2011Applicant: Hoffman/Barrett, L.L.C.Inventors: Anthony G.M. Barrett, Evan R. Trivedi, Brian M. Hoffman
-
Patent number: 8029766Abstract: The invention is directed to a probe-type imaging device useful to visualize interior surfaces, e.g., the lumen of blood vessels. Specifically, the probe-type device is particularly useful for direct tissue imaging in the presence or absence of molecular imaging agents.Type: GrantFiled: June 16, 2005Date of Patent: October 4, 2011Inventors: David R. Elmaleh, Rick A. Rogers, Hjalmar Brismar
-
Patent number: 8030342Abstract: The present invention is directed to a dendritic polyamidoamine phthalocyanine derivative which is useful as, for example, a fluorescent material or a photodynamic therapeutic drug for cancer. The derivative is represented by the following formula (1): (wherein each member of one to eight of R1 to R8 is a polyamidoamine dendron represented by the following formula (a): (wherein p is a number from 1 to 4; R9 represents —NH(CH2)tNH2 or OR10 (wherein R10 represents an alkyl group); and each of l, m, q, and t is a number from 1 to 8), and each member of the remainder represents a hydrogen atom; M represents a metal atom having a valency of two or more; and a ring marked with (N) is a benzene ring, a pyridine ring, or a pyrazine ring).Type: GrantFiled: September 13, 2007Date of Patent: October 4, 2011Assignee: Nihon UniversityInventors: Keiichi Sakamoto, Seiko Kanazawa
-
Publication number: 20110189102Abstract: The present disclosure provides embodiments of a new class of hydroxylated quantum dots. The quantum dots have a hydroxylated coat disposed thereon, and which serves to minimize non-specific cellular binding and to maintain the small size of quantum dot probes. Embodiments of the coated quantum dots of the disclosure are just slightly larger than the diameter of uncoated quantum dots, and are bright with high quantum yields. They are also very stable under both basic and acidic conditions. Embodiments of the hydroxylated quantum dots result in significant reductions in non-specific binding relative to that of carboxylated dots, and to protein and PEG-coated dots. Embodiments of the disclosure are advantageous in a range of biological applications where non-specific binding is a major problem, such as in multiplexed biomarker staining in cells and tissues, detection of biomarkers in body fluid samples (blood, urine, etc.), as well as live cell imaging.Type: ApplicationFiled: February 5, 2009Publication date: August 4, 2011Inventors: Brad A. Kairdolf, Shuming Nie
-
Publication number: 20110182825Abstract: Mitochondrial function is measured. Repetitive or continuous measurements are performed of prompt red fluorescence, emerging from the skin due to PpIX build up, and/or delayed fluorescence of PpIX. An estimate of the rate of PpIX generation is used as an indicator of mitochondrial integrity and ATP availability. Mitochondrial oxygen tension is determined from the delayed fluorescence lifetime of PpIX. When blood supply to the measurement volume is interrupted or reduced, the resulting changes to the mitochondrial oxygen tension allow an estimation of information about the kinetics of oxygen consumption in the mitochondria, such as the maximum rate of oxygen consumption as well as the Michaelis-Menten constant, providing information about the oxygen affinity of the mitochondrial respiratory chain.Type: ApplicationFiled: August 14, 2009Publication date: July 28, 2011Inventor: Egbert G. Mik
-
Publication number: 20110177007Abstract: The invention provides optical agents, including compositions, preparations and formulations, and methods of using and making optical agents. Optical agents of the present invention include dyes, and derivatives thereof, having a fused ring backbone structure having dithienopyrrole core. In some embodiments, dyes of the present invention are dithienopyrrole dyes having a dithienopyrrole core optionally functionalized to provide useful optical, biological, pharmacokinetic and/or physical properties.Type: ApplicationFiled: September 29, 2009Publication date: July 21, 2011Inventors: Raghavan Rajagopalan, William L. Neumann, Amruta Poreddy, John N. Freskos, Richard B. Dorshow
-
Publication number: 20110177006Abstract: The invention provides optical agents, including compositions, preparations and formulations, and methods of using and making optical agents. Optical agents of the present invention include dyes, and derivatives thereof, having a fused ring backbone structure having dithienofuran core. In some embodiments, dyes of the present invention are dithienofuran dyes having a dithienofuran core optionally functionalized to provide useful optical, biological, pharmacokinetic and/or physical properties.Type: ApplicationFiled: September 29, 2009Publication date: July 21, 2011Inventors: Raghavan Rajagopalan, William L. Neumann, Amruta Poreddy, John N. Freskos, Richard B. Dorshow
-
Patent number: 7977474Abstract: The invention provides the use of a compound of Formula (I), or metallated derivative thereof, in the preparation of a medicament for killing or attenuating the growth of microorganisms by a method which does not comprise exposing the compound to a photodynamic therapy light source or a sonodynamic therapy ultrasound source Formula (I) wherein X1, X2, X3, X4, Yi, Y2, Y3, Y4 and Z have meanings given in the description. Preferably, the microorganisms are selected from the group consisting off bacteria, mycoplasmas, yeasts, fungi and viruses.Type: GrantFiled: June 22, 2005Date of Patent: July 12, 2011Assignee: Destiny Pharma Ltd.Inventors: William G. Love, William Rhys-Williams, Derek Brundish
-
Publication number: 20110117029Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<?>, COS<?>, SO3<?>, PO3<2?>, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.Type: ApplicationFiled: November 9, 2010Publication date: May 19, 2011Applicant: Yeda Research and Development Co., Ltd.Inventors: Avigdor SCHERZ, Alexander Brandis, Ohad Mazor, Yoram Salomon, Hugo Scheer
-
Publication number: 20110091390Abstract: A tetrapyrollic photosensitizer compound having at least one pendant —CH2CH2CON(CH2CON(CH2COOH)2)2 or —N(CH2COOH)2 group or esters thereof said tetrapyrollic compound being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide. Desirably the compound has the formula: or a pharmaceutically acceptable derivative thereof, wherein R1—R8 and R10 are various substituents and R9 is substituted or unsubstituted —CH2CH2CON(CH2CON(CH2COOH)2)2; or —N(CH2COOH)2. The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection of the compound.Type: ApplicationFiled: October 26, 2010Publication date: April 21, 2011Applicant: Health Research, Inc.Inventors: Ravindra K. Pandey, Amy Gryshuk, Lalit Goswami, William Potter, Allan Oseroff
-
Publication number: 20110091373Abstract: A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and an imaging agent and methods for making and using same.Type: ApplicationFiled: October 21, 2010Publication date: April 21, 2011Applicants: Health Research, Inc., The Research Foundation of State University of New York, Regents of the University of MichiganInventors: Ravindra K. Pandey, Raoul Kopelman, Anurag Gupta, Munawwar Sajjad
-
Publication number: 20100303732Abstract: The present invention relates to the provision of nanoparticular formulations comprising a PEG-alkyl block copolymer and a near infrared fluorescent dye, the preparation of these nanoparticular formulations, pharmaceutical compositions comprising the nanoparticular formulations of the present invention, as well as their use as contrast medium.Type: ApplicationFiled: September 12, 2008Publication date: December 2, 2010Inventor: Malte Bahner
-
Patent number: 7820143Abstract: A tetrapyrollic photosensitizer compound having at least one pendant —CH2CH2CON(CH2CON(CH2COOH)2)2 or —N(CH2COOH)2 group or esters thereof said tetrapyrollic compound being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide. Desirably the compound has the formula: or a pharmaceutically acceptable derivative thereof, wherein R1-R8 and R10 are various substituents and R9 is substituted or unsubstituted —CH2CH2CON(CH2CON(CH2COOH)2)2; or —N(CH2COOH)2. The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection of the compound.Type: GrantFiled: February 19, 2009Date of Patent: October 26, 2010Assignee: Health Research, Inc.Inventors: Ravindra K. Pandey, Amy Gryshuk, Lalit Goswami, William Potter, Allan Oseroff
-
Publication number: 20100247447Abstract: Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Such microaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions favoring the production of small aggregates for improved filter sterilization.Type: ApplicationFiled: June 19, 2009Publication date: September 30, 2010Inventors: Ronald Erwin Boch, Dev Mitra Ranji Singh, Iman Karmadi
-
Publication number: 20100239506Abstract: The present invention provides a method for detection or determination of vitamin C by luminescence that employs a redox-responsive fluorogenic probe consisting of porphyrin or phthalocyanine with a nitroxide radical(s), or that employs a liposome preparation comprising the said redox-responsive fluorogenic probe. The present method can overcome the problems of prior art methods, and in particular, are applicable for bioimaging to allow elucidation of the behavior of vitamin C in vivo.Type: ApplicationFiled: March 17, 2010Publication date: September 23, 2010Applicant: THE UNIVERSITY OF TOKYOInventors: Kazuyuki Ishii, Kensuke Kubo, Kikuo Komori, Yasuyuki Sakai